Insulin action and fibrinolysis influenced by vitamin E in obese Type 2 diabetes mellitus

Diabetes Res Clin Pract. 1999 Apr;44(1):27-33. doi: 10.1016/s0168-8227(99)00010-8.

Abstract

Increased oxidative stress, hypofibrinolysis and insulin resistance are present in obese Type 2 diabetic patients. It is supposed that treatment with antioxidant alpha-tocopherol (vitamin E) could not only decrease free radical production, but also ameliorate insulin action. We evaluated the effect of 3 months administration of vitamin E (600 mg daily) on insulin action examined by hyperinsulinemic clamp in 11 obese Type 2 diabetic patients. Oxidative stress and fibrinolysis were also determined. The administration of vitamin E caused a decrease of glucose disposal rate (26.6 +/- 9.5 vs 21.3 +/- 7.5 micromol/kg/min, P < 0.02) and of metabolic clearance rate of glucose (3.7 +/- 1.6 vs 2.9 +/- 0.8 ml/kg/min. P < 0.02). A decrease of insulin receptor number was observed on erythrocytes after vitamin E (284 +/- 84 vs 171 +/- 59 pmol/l, P < 0.01). Significantly higher plasma malondialdehyde (MDA) concentration documented an increased oxidative stress in diabetic patients as compared with healthy persons (3.13 +/- 0.68 vs 1.89 +/- 0.18 micromol/l, P<0.001). An inverse relationship was found between MDA concentration and insulin sensitivity expressed by glucose disposal rate (r = -0.73). Vitamin E further worsened the hypofibrinolysis documented by a decrease of tissue plasminogen activator (P < 0.01) without changes in its inhibitor PAI-1. In conclusion. our results demonstrate that higher doses of vitamin E may further deteriorate insulin action and fibrinolysis in obese Type 2 diabetic patients.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Blood Pressure
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / physiopathology*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology*
  • Erythrocytes / drug effects
  • Erythrocytes / metabolism
  • Female
  • Fibrinolysis / drug effects
  • Fibrinolysis / physiology*
  • Glucose Clamp Technique
  • Humans
  • Infusions, Intravenous
  • Insulin / administration & dosage
  • Insulin / pharmacology*
  • Male
  • Malondialdehyde / blood
  • Middle Aged
  • Obesity*
  • Oxidative Stress
  • Plasminogen Activator Inhibitor 1 / blood
  • Receptor, Insulin / blood
  • Reference Values
  • Tissue Plasminogen Activator / blood
  • Vitamin E / therapeutic use*

Substances

  • Blood Glucose
  • Insulin
  • Plasminogen Activator Inhibitor 1
  • Vitamin E
  • Malondialdehyde
  • Receptor, Insulin
  • Tissue Plasminogen Activator